The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC).
 
Anita Ahmed Turk
No Relationships to Disclose
 
Sam Joseph Lubner
No Relationships to Disclose
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - EMD Serono; Flatiron Health; Gerson Lehrman Group; Lilly
Research Funding - EMD Serono (Inst); Taiho Pharmaceutical (Inst)
 
Noelle K. LoConte
Consulting or Advisory Role - AstraZeneca; Bayer; Celgene
 
Daniel Mulkerin
No Relationships to Disclose
 
David H. Kim
Stock and Other Ownership Interests - Cellectar; Elucent Medical
 
Kristina Matkowskyj
No Relationships to Disclose
 
Sharon M. Weber
No Relationships to Disclose
 
Daniel Abbott
No Relationships to Disclose
 
Jens C. Eickhoff
Research Funding - Sanofi Pasteur (Inst)
 
Michael F. Bassetti
Consulting or Advisory Role - Guidepoint Pharmacy; Third Bridge
Research Funding - AstraZeneca; EMD Serono; Merck
Travel, Accommodations, Expenses - ViewRay
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech/Roche; Novocure; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)